Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) — Stella

Recruiting

Back to Head and Neck Squamous Cell Carcinoma trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Key details

Phase

Large-scale testing

Sponsor

Sun Yat-sen University

Collaborators

Fujian Medical University Union Hospital, Guangzhou Panyu Central Hospital

Enrollment target

~220 participants

Started

October 2021

Primary completion

October 2026

Age range

18 Years – 70 Years

Last updated March 2022

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov